Literature DB >> 11821691

Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes.

Kenji Kashiwagi1, Katsuhiko Tsukamoto, Michihiro Suzuki, Shigeo Tsukahara.   

Abstract

PURPOSE: The authors sought to investigate the cellular mechanism of melanogenesis by prostaglandin antiglaucomatous compounds, isopropyl unoprostone (referred to as unoprostone) and latanoprost, and to quantitatively compare their effect on melanogenesis using cultured mouse epidermal melanocytes.
METHODS: M1, M2, and the acid of latanoprost, all of which are possible intraocular metabolites of unoprostone or latanoprost, were used. Tested prostaglandin-related compounds (final concentration range, 1 micromol/L-10 nmol/L) were administrated to the culture medium of purely cultured mouse melanoblasts, melan-A, once daily for 2 weeks. One micromole per liter prostaglandin F(2 alpha) solution was administered in parallel. Radioisotope assays were used to measure the total melanin synthesis and the activity of tyrosinase in converting tyrosine to L-3,4-dihydroxyphenylalanine, which is a rate-limiting reaction in melanogenesis. The effects of prostaglandin F(2 alpha), M1, or M2 on proliferation of melan-A were examined.
RESULTS: M1, M2, and acid of latanoprost but not prostaglandin F(2 alpha), significantly enhanced tyrosinase activity. M2 and acid of latanoprost more greatly enhanced tyrosinase activity than did M1. None of the tested compounds significantly altered the proliferation and total melanin synthesis of melan-A.
CONCLUSIONS: Both unoprostone and latanoprost enhanced tyrosinase activity. These prostaglandin-related compounds may influence the nature of melanin and result in pigmentation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821691     DOI: 10.1097/00061198-200202000-00011

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  3 in total

1.  Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost.

Authors:  K Kashiwagi; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

Review 2.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10

3.  Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice.

Authors:  Laura M Dutca; Danielle Rudd; Victor Robles; Anat Galor; Mona K Garvin; Michael G Anderson
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.